Vanda Pharmaceuticals (VNDA) EBIT (2010 - 2026)

Vanda Pharmaceuticals has disclosed EBIT across 17 years of filings, most recently posting -$50.2 million for Q1 2026.

• EBIT for Q1 2026 came in at -$50.2 million, down 22.41% year-over-year; the trailing twelve-month figure through Mar 2026 was -$160.4 million (down 121.34% YoY), and the FY2025 annual result was -$151.2 million, down 271.79% from the prior year.
• EBIT came in at -$50.2 million for Q1 2026 at Vanda Pharmaceuticals, down from -$40.4 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $6.6 million in Q4 2022 to a low of -$50.2 million in Q1 2026.
• The 5-year median for EBIT is -$9.2 million (2024), against an average of -$14.7 million.
• Across the five-year window, EBIT jumped 126.13% in 2023 and tumbled 560.83% in 2024, its largest moves.
• Vanda Pharmaceuticals' EBIT stood at $6.6 million in 2022, then tumbled by 207.01% to -$7.1 million in 2023, then plunged by 44.9% to -$10.3 million in 2024, then plunged by 292.58% to -$40.4 million in 2025, then decreased by 24.46% to -$50.2 million in 2026.
• The last three EBIT figures came in at -$50.2 million (Q1 2026), -$40.4 million (Q4 2025), and -$31.3 million (Q3 2025), per Business Quant data.